EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Heat Shock Transcription Factor 4 Enhances the Efficacy of Cabozantinib and Immune Checkpoint Inhibitors in Renal Cell Carcinoma

Saeki Saito, Hirofumi Yoshino iD, Seiya Yokoyama iD, Mitsuhiko Tominaga, Gang Li, Junya Arima iD, Ichiro Kawahara, Ikumi Fukuda, Akihiko Mitsuke, Takashi Sakaguchi, Satoru Inoguchi, Ryosuke Matsushita und 4 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26041776 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Saeki Saito und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Anilides, Pyridines, Kidney Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kaken Pharmaceutical (Japan), the Kodama Memorial Fund for Medical Research, Japan Society for the Promotion of Science, KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recently, immune checkpoint inhibitors (ICIs) and cabozantinib, a tyrosine kinase inhibitor (TKI), have been used to treat renal cell carcinoma (RCC); the combination of these agents has become a standard treatment for RCC. TKIs generally target vascular endothelial growth factor. However, cabozantinib is characterized by its targeting of MET. Therefore, cabozantinib can be used as a late-line therapy for TKI-resistant RCC. According to data from The Cancer Genome Atlas (TCGA), heat shock transcription factor 4 (HSF4) expression is higher in RCC tissues than in normal renal tissues. HSF4 binds to the MET promoter in colorectal carcinoma to enhance MET expression and promote tumor progression. However, the functional role of HSF4 in RCC is unclear. We performed loss-of-function assays of HSF4, and our results showed that HSF4 knockdown in RCC cells significantly decreased cell functions. Moreover, MET expression was decreased in HSF4-knockdown cells but elevated in sunitinib-resistant RCC cells. The combination of cabozantinib and HSF4 knockdown reduced cell proliferation in sunitinib-resistant cells more than each monotherapy alone. Furthermore, HSF4 knockdown combined with an ICI showed synergistic suppression of tumor growth in vivo. Overall, our strategy involving HSF4 knockdown may enhance the efficacy of existing therapies, such as cabozantinib and ICIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellAnilidesPyridinesKidney NeoplasmsHeat Shock Transcription FactorsImmune Checkpoint InhibitorsTranscription FactorsHumansAnimalsCell Line, TumorMiceCell ProliferationXenograft Model Antitumor AssaysGene Expression Regulation, NeoplasticProto-Oncogene Proteins c-metDrug Resistance, NeoplasmSunitinib

Stichwörter der Autor:innen

METcabozantinibheat shock transcription factor 4immune checkpoint inhibitorrenal cell carcinoma

Substanzen

cabozantinibAnilidesPyridinesHeat Shock Transcription FactorsImmune Checkpoint InhibitorsProto-Oncogene Proteins c-metTranscription FactorsSunitinib

Autor:innen und Institutionen

  • Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.
  • Department of Pathology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8544, Japan.

ORCID-Profile: Hirofumi Yoshino, Seiya Yokoyama, Junya Arima, Shuichi Tatarano

Förderung

  • Kaken Pharmaceutical (Japan)
  • the Kodama Memorial Fund for Medical Research
  • Japan Society for the Promotion of Science, KAKENHI
  • Kodama Memorial Fund for Medical Research

Zitieren

APA

Saito, S., Yoshino, H., Yokoyama, S., Tominaga, M., Li, G., Arima, J., Kawahara, I., Fukuda, I., Mitsuke, A., Sakaguchi, T., Inoguchi, S., Matsushita, R., Yamada, Y., Tatarano, S., Tanimoto, A., & Enokida, H. (2025). Targeting Heat Shock Transcription Factor 4 Enhances the Efficacy of Cabozantinib and Immune Checkpoint Inhibitors in Renal Cell Carcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26041776

Vancouver

Saito S, Yoshino H, Yokoyama S, Tominaga M, Li G, Arima J, et al. Targeting Heat Shock Transcription Factor 4 Enhances the Efficacy of Cabozantinib and Immune Checkpoint Inhibitors in Renal Cell Carcinoma. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26041776

BibTeX
@article{Saito2025,
  author = {Saito, Saeki and Yoshino, Hirofumi and Yokoyama, Seiya and Tominaga, Mitsuhiko and Li, Gang and Arima, Junya and Kawahara, Ichiro and Fukuda, Ikumi and Mitsuke, Akihiko and Sakaguchi, Takashi and Inoguchi, Satoru and Matsushita, Ryosuke and Yamada, Yasutoshi and Tatarano, Shuichi and Tanimoto, Akihide and Enokida, Hideki},
  title = {Targeting Heat Shock Transcription Factor 4 Enhances the Efficacy of Cabozantinib and Immune Checkpoint Inhibitors in Renal Cell Carcinoma},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26041776}
}
Kostenlos starten →